A trial looking at tusamitamab ravtansine for non small cell lung cancer (CARMEN-L03)
Cancer type:
Status:
Phase:
This trial compared tusamitamab ravtansine (SAR408701) to docetaxel to treat non small cell lung cancer.
It was for people with non small cell cancer that has spread to another part of the body.
More about this trial
Docetaxel is a chemotherapy drug that doctors use to treat non small cell lung cancer.
Some cancers including lung cancers have a protein called CEACAM5 on their surface.
Tusamitamab ravtansine is a antibody drug conjugate. It is a combination of a 
and a chemotherapy drug called ravtansine or DM4. The monoclonal antibody attaches to the CEACAM5 protein on the cancer cell and then releases DM4 into the cancer cell.
Researchers thought that tusamitamab ravtansine might be as good as or better than docetaxel for non small lung cancer.
In this trial half the people were to have tusamitamab ravtansine. And the other half were to have docetaxel.
The aims of this trial were to find out:
- how well tusamitamab ravtansine works compared to docetaxel
- more about the side effects of tusamitamab ravtansine
- what happens to it in the body
- how it affects
quality of life
Summary of results
This trial closed earlier than planned. This was because none of the hospitals in the UK recruited any patients.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Jo Evans
Supported by
Sanofi
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
